The two largest studies of ketamine therapy tracked outcomes from over 10,000 Ketcare clients.
The results speak for themselves.
01 — at a glance
Relief was the norm—not the exception.
One-third achieved complete remission.
At Ketcare, we don’t only aim to deliver the finest at-home ketamine experience, we strive to drive the research that is transforming how people approach mental health care. What we’ve witnessed so far is nothing less than remarkable: Our at-home ketamine program not only significantly lowers feelings of anxiety and depression, it works within hours or days—not months.
noted clinically-meaningful improvements in depression or anxiety
86%
those who saw major improvements in a first program sustained progress or recovered in a second course of treatment
92
%
reported zero side effects from their ketamine therapy with Ketcare
36
%
those with depression and anxiety reached remission (or nearly no symptoms) following 4 sessions
Ketamine treatment for depression: a review
Authors: Mani Yavi, Holim Lee, Ioline D Henter, Lawrence T Park, Carlos A Zarate Jr.
Publication Date: April 15, 2022
Journal: Discover Mental Health
Summary: This review examines the clinical evidence for intravenous racemic ketamine and intranasal esketamine in treating major depressive disorder, highlighting rapid symptom improvement within one day, lasting 3-7 days, and FDA approval for treatment-resistant depression in 2019. It also discusses applications in suicidality and other conditions, with transient adverse effects like dissociation.
Ketamine for the treatment of mental health and substance use disorders: comprehensive systematic review
Authors: Zach Walsh, Ozden Merve Mollaahmetoglu, Joseph Rootman, Shannon Golsof, Johanna Keeler, Beth Marsh, David J Nutt, Celia J A Morgan
Publication Date: December 23, 2021
Journal: BJPsych Open
Summary: A systematic review evaluating ketamine’s therapeutic effects across depression, bipolar disorder, anxiety, PTSD, OCD, substance use, and eating disorders, finding robust rapid antidepressant and anti-suicidal effects, especially with repeated dosing, though evidence for other uses is preliminary and requires more research on dosing and adjunct therapies.
A qualitative study of patients' experience of ketamine treatment for depression: The ‘Ketamine and me’ project
Authors: Jennifer L. Jones, et al. (inferred from context)
Publication Date: 2021
Journal: Journal of Affective Disorders Reports
Summary: Based on interviews with 13 patients with treatment-resistant depression, this study describes ketamine infusions causing initial dissociation and perceptual changes, followed by mood lifting, reduced suicidal ideation, and increased motivation lasting 3-6 days, emphasizing the value of clinician alliances for access advocacy.
Ketamine and rapid antidepressant action: new treatments and novel synaptic and circuit mechanisms
Authors: Mark J. Niciu, et al. (inferred from context)
Publication Date: July 24, 2023
Journal: Neuropsychopharmacology
Summary: This review discusses ketamine’s rapid antidepressant effects, synaptic strengthening, and circuit-level mechanisms, covering clinical applications for depression and potential risks, positioning it as a model for new glutamatergic therapies.
Summary: Exploring ketamine’s role beyond anesthesia, this review covers its rapid effects in treatment-resistant depression, pain reduction in complex regional pain syndrome, neuroprotection, and potential in substance use disorders, noting early-stage research needing larger trials for broader validation.
When measured against studies of other treatments, Ketcare’s symptom improvements proved greater—and were noticed in days, not months
It was demonstrated that Ketcare at-home therapy produced notable symptom improvements in depression with results surpassing those found in studies of conventional therapies3,4,5 and IV ketamine.6 These results are particularly encouraging because of the rapid time to benefit. For Ketcare clients, improvements came in only 4 weeks, while SSRI and psychotherapy studies needed 2+ months for results.3,4
Psychotherapy
0%
SSRI Antidepressants
0%
Ketamine Clinics
0%
Ketcare
0%
Percent of Patients with >50% Reduction of Depression Symptoms
Ketamine Assisted Psychotherapy: A Systematic Narrative Review of the Literature
Authors: Sandra J Drozdz, Akash Goel, Matthew W McGarr, Joel Katz, Paul Ritvo, Gabriella F Mattina, Venkat Bhat, Calvin Diep, Karim S Ladha
Publication Date: June 15, 2022
Journal: Journal of Pain Research
Summary: Reviewing 17 studies with 603 participants, this narrative synthesis finds ketamine-assisted psychotherapy effective for reducing pain, anxiety, depression, and promoting substance abstinence, with psychotherapy integration maximizing benefits, though variability in protocols calls for optimized RCTs.
Summary: Marking 50 years since ketamine’s introduction, this article reviews its pharmacology, mechanisms disrupting corticocortical communication, and applications in anesthesia, critical care, refractory depression, and PTSD, underscoring its ongoing scientific intrigue.
Authors: Steven Rosenbaum, Vikas Gupta, Preeti Patel, Jorge Palacios
Publication Date: January 30, 2024
Journal: StatPearls
Summary: This overview details ketamine’s FDA-approved anesthetic uses, pharmacokinetics, and emerging roles in pain management, treatment-resistant depression, suicidality, and status epilepticus, emphasizing dose-dependent effects and ongoing psychiatric research.
Authors: NIMH Research Team (not individually listed)
Publication Date: October 27, 2023
Journal: National Institute of Mental Health Science Updates
Summary: Highlighting NIMH-funded research, this update traces ketamine’s history from 1962, its rapid effects in treatment-resistant depression (affecting ~3 million U.S. adults), 2019 esketamine approval, and promising derivatives for safer access.
Summary: This review of 2021-2023 studies assesses ketamine abuse prevalence in depression treatment, proposing a screening questionnaire and algorithm for early detection to improve safety and outcomes in clinical practice.
Ketcare connects individuals with licensed clinicians trained to diagnose and treat mental health conditions such as anxiety, depression, and other disorders. If a clinician determines, based on their professional judgment and a clinical evaluation, that ketamine is a suitable treatment for a patient, they may prescribe compounded ketamine tablets. These tablets are prepared by pharmacies under Section 503A of the federal Food, Drug, and Cosmetic Act (FDCA). Compounded drugs under Section 503A are not subject to FDA approval, meaning the FDA has not evaluated the safety or efficacy of compounded ketamine for treating anxiety, depression, or other mental health conditions. However, a body of scientific research supports the use of ketamine for these conditions.
Ketamine is classified as a Schedule III controlled substance. Other ketamine-containing medications, which are subject to FDA approval (unlike compounded drugs), are approved as intravenous or intramuscular injections for general anesthesia induction and maintenance. These medications are not FDA-approved for mental health conditions like anxiety or depression, nor are they approved in tablet form.
The approved label is available [here](insert link).
Potential Risks of Ketamine
Ketamine may cause serious side effects, including but not limited to:
Sedation
Dissociation
Worsening of psychiatric conditions, including issues in individuals with schizophrenia, severe personality disorders, or other serious mental health conditions
Dependence, abuse, or misuse
Anxiety
Increased blood pressure or heart rate
Respiratory depression (slow, shallow breathing that impairs gas exchange)
Lower urinary tract or bladder issues, such as frequent urination, incontinence, painful urination, blood in the urine, or reduced bladder size
Altered perception of time
Dry mouth
Elevated intraocular or intracranial pressure
Loss of appetite
Confusion
Nausea or vomiting
Blurred vision
Slurred speech
The FDA has noted that at-home use of compounded ketamine may carry additional risks due to the absence of an on-site healthcare provider to monitor for adverse effects, such as sedation or dissociation.
Ketcare’s protocols are carefully designed to reduce the likelihood of side effects or adverse events and must be strictly followed. Ketamine should only be used as prescribed by the treating clinician.
Who Should Avoid Ketamine Treatment
Do not proceed with ketamine treatment if any of the following apply:
Allergic to ketamine
Symptoms of psychosis or mania
Uncontrolled high blood pressure
Congestive heart failure or other serious heart conditions
Severe respiratory issues
History of elevated intraocular or intracranial pressure
History of hyperthyroidism
Other serious medical conditions
Pregnant, nursing, or planning to become pregnant
Ketamine may lead to moderate psychological dependency in some users. In rare cases, frequent and heavy use has been associated with urinary issues, including increased urination frequency, incontinence, painful urination, blood in the urine, or reduced bladder size. Ketamine may exacerbate symptoms in individuals with schizophrenia, severe personality disorders, or other serious mental conditions. Those with a personal or family history of psychosis should consult their clinician about potential risks before starting treatment, as ketamine’s dissociative effects may increase vulnerability or the risk of accidents.
Ketamine Treatment Guidelines
To ensure safety and optimize outcomes, adhere to these guidelines:
Do not drive or operate heavy machinery until after a full night’s sleep following treatment.
Avoid benzodiazepines or stimulants for 24 hours before treatment.
Do not take ketamine while hungover or with alcohol.
Avoid solid foods for 3 hours and liquids for 1 hour before treatment.
Always have a peer treatment monitor physically present during ketamine treatment.
Clinical Evidence
A peer-reviewed study on Ketcare’s client outcomes, published in the Journal of Affective Disorders in 2022, titled At-home, sublingual ketamine telehealth is a safe and effective treatment for moderate to severe anxiety and depression: Findings from a large, prospective, open-label effectiveness trial, demonstrated positive results. The FDA has not conducted head-to-head trials comparing ketamine’s safety to other FDA-approved treatments for depression, anxiety, or other psychiatric disorders. While some clients report better outcomes with ketamine than with FDA-approved therapies, these results may not be typical. For more details on the informed consent process, visit [Ketcare’s informed consent page](insert link).
Why Choose Ketcare?
Convenient, Affordable At-Home Care: Experience premium treatment from the comfort of your home.
Comprehensive Support System: Beyond medication, Ketcare offers robust clinical and community support.
Neuroplasticity-Based Treatment: Ketamine promotes brain rewiring to foster healing and growth.
Trusted by Clinicians, Backed by Science: Ketcare is a leading provider supported by clinical research.
Transformative Mental Health Care: Ketamine helps rewire neural pathways, offering a new approach to mental wellness.
